Pupu Li
Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for relapsed/refractory (R/R) B-cell malignancies, including B-cell non-Hodgkin lymphoma (B-NHL), B-cell acute lymphoblastic leukemia (B-ALL), and related diseases. …